Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Latest News
thumbnail
Therapeutic ClassHow and why AstraZeneca’s oncology eyes turned to cell therapies
How and why AstraZeneca turned to cell therapy for oncology
Cell therapies will play an increasingly important position in AstraZeneca’s broad oncology pipeline, an SVP told delegates at Biotech Week Boston (BWB) last month.
Deal-Making
Letter urges FTC to block Novo’s $16.5bn Catalent purchaseLetter urges FTC to block Novo’s $16.5bn Catalent purchase
Consumer advocacy groups, healthcare unions, and a US senator are all asking for government intervention.
Deal-Making
Cellular Origins and Fresenius Kabi partner to drive automation in CGT manufacturingCellular Origins and Fresenius Kabi partner to drive automation in CGT manufacturing
The deal seeks to improve manufacturing efficiency, building upon a busy summer for the TTP subsidiary.
Facilities & Capacity
CDMO AGC places CO plant on ice amid turbulent CGT economyCDMO AGC places CO plant on ice amid turbulent CGT economy
AGC Biologics confirms it has shut down “most operations” at its vacillating Longmont facility and is laying off 95 employees globally.
Facilities & Capacity
AtomVie partners with Radiopharm Ventures to produce radioantibody for trialsRadiopharm Ventures to produce radioantibody for AtomVie
The CDMO will manufacture the solid-tumor therapy primarily at a new facility in Ontario, Canada.
Global Markets
ReiThera partners with Sabin to send Marburg vaccine to RwandaReiThera partners with Sabin to send Marburg vaccine to Rwanda
The Phase II trial will target frontline workers against a disease that can reach 88% mortality rates when untreated.
Regulations
Size matters when navigating BIOSECURE, says consultantSize matters when navigating BIOSECURE, says consultant
Smaller innovators are more likely to be upended by US legislation aimed at restricting working with China-based CDMOs like WuXi Biologics, according to Latham Biopharm.
Regulations
Letter urges FTC to block Novo’s $16.5bn Catalent purchaseLetter urges FTC to block Novo’s $16.5bn Catalent purchase
Consumer advocacy groups, healthcare unions, and a US senator are all asking for government intervention.
Regulations
Size matters when navigating BIOSECURE, says consultantSize matters when navigating BIOSECURE, says consultant
Smaller innovators are more likely to be upended by US legislation aimed at restricting working with China-based CDMOs like WuXi Biologics, according to Latham Biopharm.
Therapeutic Class
How and why AstraZeneca’s oncology eyes turned to cell therapiesHow and why AstraZeneca turned to cell therapy for oncology
Cell therapies will play an increasingly important position in AstraZeneca’s broad oncology pipeline, an SVP told delegates at Biotech Week Boston (BWB) last month.
Facilities & Capacity
AtomVie partners with Radiopharm Ventures to produce radioantibody for trialsRadiopharm Ventures to produce radioantibody for AtomVie
The CDMO will manufacture the solid-tumor therapy primarily at a new facility in Ontario, Canada.
Upstream & Downstream Processing
Now open: Millipore’s Maryland facility slashes virus testing timeNow open: Millipore’s Maryland facility slashes virus testing time
The 250,000 square-foot site will house biosafety testing, analytical development, and cell-banking manufacturing services.
Upstream & Downstream Processing
Allterum partners with GBI to manufacture mAb for clinical trialAllterum partners with GBI to manufacture mAb for clinical trial
The Florida-based contract development and manufacturing organization (CDMO) will produce an antibody for acute lymphoblastic leukemia (ALL).